Beta Drugs Ltd

- No current or immediate plans for fundraising through debt or equity were mentioned. - Rahul Batra stated that for reaching the target of Rs. 450-500 crores revenue, the company does not require any external funds. - Planned CAPEX of Rs. 30-35 crores over the next 2 years will be funded entirely through internal cash accruals. - Focus is on internal growth, business operations, and migrating to the Mainboard without involving fundraising activities. - No discussions have been held regarding share split or issuing bonus shares to improve liquidity; the focus remains on business growth and Mainboard migration.

- Total planned CAPEX for the next 2 years: Rs. 30-35 crores, funded through internal cash accruals. - Major CAPEX focus on setting up a cosmetology manufacturing plant by FY26 to expand SKUs from 14 to 40-50. - Additional CAPEX expected for acquiring marketing authorizations (MAs) post-EU GMP audit to speed up product launches in regulated markets. - No further oncology capacity expansion planned until sales reach Rs. 500 crores; investments will instead focus on MA acquisitions. - Expansion includes increasing efforts in dermatology and cosmetology manufacturing facilities. - CAPEX related to asset purchase mainly involves marketing authorizations for faster market entry rather than machinery. - Current cosmetology CAPEX estimated around Rs. 30-35 crores.

- Company expects a sales growth of 25%-30% for FY25, continuing previous growth trends. - Oncology segment projected to grow to Rs. 450-500 crores within 2 years. - Cosmetology/dermatology segment aims to reach Rs. 30-40 crores in revenue in next 3-5 years, starting from Rs. 1 crore sales in April FY24 and targeting Rs. 14-15 crores in FY24-25. - Exports expected to increase significantly, targeting 35% of total business volume over next 2-3 years with focus on regulated markets like Colombia, Mexico, Brazil, and Southeast Asia. - Company plans to increase number of SKUs in cosmetology from current 14 to 40-50 by FY25. - CAPEX of Rs. 30-35 crores planned over next 2 years (internal accrual-funded) mainly for cosmetology plant (to start FY26) and acquiring marketing authorizations post EU GMP audit. - Overall strategy focuses on brand creation, sales, profitability, and migration to Mainboard within 2 months to improve visibility and liquidity.

- Beta Drugs aims to sustain a sales growth rate of 25% to 30% for FY25 and beyond. - The company plans to improve EBITDA margins to 24%-26% in FY24-25, after a decline due to high platins raw material costs and cosmetology division losses. - Oncology segment EBITDA margin stands at 22.8%, excluding cosmetology losses, with a focus on boosting profitability by shifting focus from platins to other products. - Cosmetology division, currently marginally profitable with Rs. 1 crore sales, targets Rs. 14-15 crore sales in FY24-25, with long-term brand-building potential. - Exports are targeted to grow significantly, expected to contribute around 35% of total revenue in future years with higher margins in regulated markets. - Management assures delivering consistent growth and profitability over the next 3-5 years with a focus on innovative oncology products and expanding dermatology and cosmetology offerings.

- The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders for Beta Drugs Limited. - The management highlights ongoing efforts including 350+ dossiers filed for regulatory approvals, with business expected to flow in the next year. - They mention participation in bulk purchase tenders (e.g., Tata Memorial Hospital), expecting to get a share of such orders, potentially benefiting the company. - The company is focusing on product launches, including 6 new NDDS approvals expected between October and March, likely boosting future sales. - The management projects 25%-30% sales growth for FY25, indicating a positive outlook on order inflows. - No direct or explicit data on the order book size or pending orders is provided in the available transcript.